Skip to main content
Assets
Natera logo
NTRA.NASDAQ
Natera
Health Care · Biotechnology

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

HQ: United StatesListed: United States

Profile & Fundamentals

Natera: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.

Profile & Fundamentals

Natera Profile & Fundamentals

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables
Explore this pageJump to a Profile & Fundamentals section

Company and Market Context

Company Profile & Ownership

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

NTRA.NASDAQ

Company profile record

Natera Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset
Natera Inc
Security type
Common Stock
Sector
Health Care
Industry
Biotechnology
HQ
🇺🇸 United States
Head office
13011 McCallen Pass, Austin, TX, United States, 78753

Leadership & scale

Chief executive
Mr. Steven Leonard Chapman
CEO year born
1979
Full-time employees
6.1K
Fiscal year end
December
IPO date
2015-07-02

Fundamentals snapshot

Updated 2026-09-16
Market Cap
USD 52.9B
P/E
--
Revenue (Q2 26)
USD 752.8M
Profit (Q2 26)
USD -67.0M
Dividend Yield
--
Revenue (FY 25)
USD 2.3B
Shares in public float
140M
Insider ownership
2.82%

Reporting & identifiers

Symbol
NTRA.NASDAQ
Listing
🇺🇸 United States | Dividend Tax: 30%
Ticker Currency
USD
Income Statement Currency
USD
Balance Sheet Currency
USD
Cash Flow Currency
USD
EPS Currency
USD
Contract Type
SPOT
ISIN
US6323071042
Asset ID
equity_9bcb5738-6092-5a90-83b0-28f2be8172b2

Ownership

Shares Outstanding

Shares OutstandingAnnual reported shares outstanding. Values in shares.45.22M71.96M98.71M125.45M152.19MJan 2017Apr 2019Jul 2021Oct 2023Jan 2026
  • Shares outstanding
Annual reported shares outstanding. Values in shares.

Top holders

  1. JPMorgan Chase & Co13,386,667 shares · 9.29% · Reported 2026-03-31
  2. T. Rowe Price Associates, Inc.12,184,876 shares · 8.45% · Reported 2026-03-31
  3. BlackRock Inc10,677,338 shares · 7.41% · Reported 2026-03-31
  4. Vanguard Capital Management, LLC6,008,496 shares · 4.17% · Reported 2026-03-31
  5. Vanguard Portfolio Management, LLC5,644,695 shares · 3.92% · Reported 2026-03-31
  6. JPMorgan Large Cap Growth I5,550,940 shares · 3.85% · Reported 2026-07-31
  7. Vanguard MStar Total Stk Mkt Idx Invest4,333,872 shares · 3.01% · Reported 2026-07-31
View more holders (8)
  1. Wellington Management Company LLP4,040,738 shares · 2.80% · Reported 2026-06-30
  2. State Street Corp3,417,472 shares · 2.37% · Reported 2026-03-31
  3. Farallon Capital Management, L.L.C.3,207,366 shares · 2.23% · Reported 2026-03-31
  4. Vanguard Small Cap Index3,126,979 shares · 2.17% · Reported 2026-07-31
  5. Duquesne Family Office LLC3,063,606 shares · 2.13% · Reported 2026-03-31
  6. Geode Capital Management, LLC2,775,928 shares · 1.93% · Reported 2026-03-31
  7. Castle Hook Partners LP2,596,276 shares · 1.80% · Reported 2026-06-30
  8. FMR Inc2,554,254 shares · 1.77% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

Revenue, Net Income, and Free Cash Flow

Revenue, Net Income, and Free Cash FlowAnnual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.-833.19M22.98M879.16M1.74B2.59BDec 2016Apr 2019Jul 2021Oct 2023Dec 2025
  • Revenue
  • Free cash flow
  • Net income
Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

Profitability Margins

Profitability MarginsAnnual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.-89.44-47.36-5.2836.878.88Dec 2016Apr 2019Jul 2021Oct 2023Dec 2025
  • Gross margin
  • Operating margin
  • Net margin
  • Free cash flow margin
Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.